Treatment of Hyperphosphatemia in Chronic Kidney Disease Stage 4
Elevated serum phosphorus is a clinically significant finding in patients with chronic kidney disease (CKD) stage 4. Targeted pharmacological management is required to bring phosphorus levels within the accepted therapeutic range.
Clinical Scenario
This protocol applies to patients with chronic kidney disease stage 4 presenting with hyperphosphatemia. Calcium-based products are often started at this stage secondary to their efficacy, safety profile, and cost.
Treatment Approach
Management is centred on calcium-based phosphate binders as the mainstay of phosphate-lowering therapy — the complete agent selection criteria, clinical decision points, and sequencing are available in the full protocol.
Treatment Target
The clinical goal is to achieve a serum phosphorus concentration of 2.7 to 4.6 mg/dL in patients not receiving dialysis.
References
- Calcium-based products are often started in stage 4 secondary to efficacy, safety, and cost.
- Approved in 1990, calcium acetate (PhosLo, various other brands) is considered a first-line therapy for lowering phosphate in CKD stage 4.
- Calcium-based phosphate binders are the mainstay of phosphate-lowering therapy in CKD stage 4.
- Overall cost of this medication is low, so it is an attractive first-line agent if hypercalcemia is not a concern.
- In general, the goal is to achieve a phosphorus concentration of 2.7 to 4.6 mg/dL in patients not receiving dialysis.
View source ↗